Star Imaging and Path Lab Secures WDRA Empanelment for Medical Services

2 min read     Updated on 11 Nov 2025, 01:54 PM
scanx
Reviewed by
Riya DScanX News Team
Overview

Star Imaging and Path Lab Limited has secured empanelment with the Warehousing Development and Regulatory Authority (WDRA) Government of India for providing medical diagnostic and laboratory services to officers, employees, and their dependents at CGHS approved rates. The three-year empanelment adds to the company's existing CGHS empanelment and advanced imaging facilities including CT scan and 3 Tesla MRI at its Vikaspuri center, strengthening its position in the diagnostic healthcare sector.

24395092

*this image is generated using AI for illustrative purposes only.

Star Imaging And Path Lab Limited has announced significant developments that continue to enhance its diagnostic capabilities and expand its patient base. The company, which specializes in providing diagnostic and healthcare services, has made strategic moves to strengthen its position in the healthcare industry through multiple government empanelments.

Advanced Imaging Facilities

Star Imaging and Path Lab has successfully added new, state-of-the-art diagnostic modalities to its existing center in Vikaspuri, New Delhi. The company has introduced:

  • CT scan facility
  • 3 Tesla MRI facility

These advanced imaging technologies are now fully operational, marking a significant upgrade to the company's diagnostic capabilities. The introduction of these high-resolution imaging services is expected to cater to a broader patient base and improve the quality of diagnostic services offered by the company.

Government Empanelments

The company has secured multiple government empanelments that substantially increase its reach and service capabilities:

Empanelment Authority Service Coverage Validity Period
CGHS Central Government Employees, PSU Employees Ongoing
WDRA Government of India Officers, employees and dependents 3 years

WDRA Empanelment Details

In the latest development, Star Imaging and Path Lab Limited has been empanelled by the Warehousing Development and Regulatory Authority (WDRA) Government of India. Key aspects of this empanelment include:

Parameter Details
Services Covered Medical diagnostic and laboratory services
Beneficiaries WDRA officers, employees, and dependents
Rate Structure CGHS approved rates
Validity 3 years from empanelment date

The WDRA empanelment allows the company to provide medical treatment, diagnosis, and laboratory services to a new segment of government employees, further expanding its institutional client base.

Strategic Implications

These developments align with Star Imaging and Path Lab's ongoing strategy to:

  1. Expand its service offerings through advanced technology
  2. Strengthen government institutional partnerships
  3. Enhance market position in diagnostic healthcare
  4. Diversify revenue streams through multiple empanelments

By securing empanelments with both CGHS and WDRA, the company has positioned itself to serve a broader spectrum of government employees and their families, creating a stable institutional revenue base.

Regulatory Compliance

The company has disclosed the WDRA empanelment in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The management has clarified that while this development strengthens the company's business prospects, it does not constitute a material event impacting the company's financial position.

As the healthcare sector continues to evolve, Star Imaging and Path Lab is focusing on technological advancements and strategic government partnerships to meet the growing demand for high-quality diagnostic services. These moves position the company for sustained growth and improved service delivery in the competitive healthcare market.

Historical Stock Returns for Star Imaging And Path Lab

1 Day5 Days1 Month6 Months1 Year5 Years
+2.98%-2.54%-20.31%-36.37%-36.37%-36.37%
Star Imaging And Path Lab
View in Depthredirect
like18
dislike
Explore Other Articles
86.50
+2.50
(+2.98%)